SCHEMBL27209652

SCHEMBL27209652

[CH2]c1cccc(Oc2cnccn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.49
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.41
HRH3 Q9Y5N1 1/20 0.41
LTA4H P09960 1/20 0.40
PTGS2 P35354 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
GCK P35557 1/20 0.36
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
SLC6A3 Q01959 1/20 0.36
MAOA P21397 1/20 0.36
GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2081785 0.80 MAOB (0.50) GAAMAPTALDH1A1KDM4ELMNA
SCHEMBL11352994 0.80 GAA (0.49) GAAMAPTALDH1A1KDM4ELMNA
SCHEMBL7354988 0.79 TLR4 (0.50) ALDH1A1KDM4EKMT2AMEN1HRH3
SCHEMBL4272944 0.78 KDM4E (0.61) GAAMAPTALDH1A1KDM4EKMT2A
SCHEMBL10547132 0.77 LMNA (0.75) ALDH1A1LMNATDP1LTA4HSMN1; SMN2
SCHEMBL8188288 0.77 ALDH1A1 (0.46) GAAMAPTALDH1A1KDM4ELMNA
SCHEMBL6203524 0.77 TAAR1 (0.50) GAAMAPTALDH1A1KDM4ELTA4H
SCHEMBL2563983 0.76 LOXL2 (0.55) GAAMAPTALDH1A1KDM4EMAOA
SCHEMBL27209672 0.76 GAA (0.46) GAAMAPTALDH1A1KDM4ELMNA
SCHEMBL27209667 0.76 GAA (0.46) GAAMAPTALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240140930-A1 PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES NEUROPN THERAPEUTICS INC. (US) 2024-05-02 US disclosed
US-20240139172-A1 PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY NeuroPn Therapeutics, Inc. (US) 2024-05-02 US disclosed
WO-2024073648-A1 PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY NeuroPn Therapeutics, Inc. (US) 2024-04-04 WO disclosed
WO-2024073680-A1 PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES NEUROPN THERAPEUTICS INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240139172-A1 PIPERIDINE UREA DERIVATIVES FOR CANCER THERAPY PDCD1, TP53, CHEK2 GAA 2265/4885MAPT 611/4885ALDH1A1 564/4885
US-20240140930-A1 PIPERIDINE UREA DERIVATIVES FOR TREATMENT OF NEURODEGENERATIVE DISEASES PRPH, EPHX1, BCHE GAA 302/4885MAPT 26/4885ALDH1A1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.